AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15129937 — intervention group
Group type: EXPERIMENTAL
Intervention: Cochlear implantation in OM-prone children.
Number of subjects: 60
Study 15129937 — intervention group
Group type: EXPERIMENTAL
Intervention: Cochlear implantation in children.
Number of subjects: 60
Study 11265021 — intervention group
Group type: EXPERIMENTAL
Intervention: Aged stored RBCs (21 or 42 days)
Number of subjects: 1
Study 11265021 — intervention group
Group type: COMPARATOR
Intervention: Washed 42-day-old RBCs
Number of subjects: 1
Study 11265021 — intervention group
Group type: COMPARATOR
Intervention: Leukoreduced RBCs
Number of subjects: 1
Study 11265021 — intervention group
Group type: EXPERIMENTAL
Intervention: Stored packed RBCs
Number of subjects: 1
Study 9035263 — intervention group
Group type: EXPERIMENTAL
Intervention: sweet soft drink
Number of subjects: 60
Study 9035263 — intervention group
Group type: EXPERIMENTAL
Intervention: filtered tap water
Number of subjects: 60
Study 9035263 — intervention group
Group type: COMPARATOR
Intervention: nothing
Number of subjects: 60
Study 9035263 — intervention group
Group type: EXPERIMENTAL
Intervention: palatable sweet food (chocolate-chip cookies)
Number of subjects: 60
Study 9035263 — intervention group
Group type: COMPARATOR
Intervention: unpalatable food (black olives)
Number of subjects: 60
Study 9035263 — intervention group
Group type: COMPARATOR
Intervention: neutral food (rice cakes)
Number of subjects: 60
Study 8067602 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C supplementation
Number of subjects: 0
Study 8067602 — intervention group
Group type: COMPARATOR
Intervention: Control group (studies not supporting vitamin C)
Number of subjects: 0
Study 3312207 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefamandole (five doses)
Number of subjects: 717
Study 3312207 — intervention group
Group type: COMPARATOR
Intervention: Single preoperative dose of cefamandole
Number of subjects: 717
Study 29610513 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive saline irrigation of the bile duct (PSIB) after stone removal
Number of subjects: 148
Study 29610513 — intervention group
Group type: COMPARATOR
Intervention: Non-preventive saline irrigation (non-PSIB)
Number of subjects: 148
Study 29610513 — intervention group
Group type: EXPERIMENTAL
Intervention: PSIB
Number of subjects: 148
Study 29610513 — intervention group
Group type: COMPARATOR
Intervention: PSIB and non-PSIB
Number of subjects: 148
Study 27432017 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital-to-community medication records scheme
Number of subjects: 124
Study 27432017 — intervention group
Group type: COMPARATOR
Intervention: Current level of hospital-to-community liaison (Control)
Number of subjects: 124
Study 24094767 — intervention group
Group type: EXPERIMENTAL
Intervention: ALN-PCS (0.400 mg/kg)
Number of subjects: 32
Study 24094767 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 23745954 — intervention group
Group type: EXPERIMENTAL
Intervention: Genuair
Number of subjects: 105
Study 23745954 — intervention group
Group type: COMPARATOR
Intervention: HandiHaler
Number of subjects: 105
Study 20189610 — intervention group
Group type: EXPERIMENTAL
Intervention: ghrelin
Number of subjects: 18
Study 20189610 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRP-6
Number of subjects: 18
Study 20189610 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH
Number of subjects: 18
Study 17398083 — intervention group
Group type: EXPERIMENTAL
Intervention: 5%M+70%E/T‐gel
Number of subjects: 0
Study 17398083 — intervention group
Group type: COMPARATOR
Intervention: 5%M/T‐gel
Number of subjects: 0
Study 17398083 — intervention group
Group type: COMPARATOR
Intervention: 70%E/T‐gel
Number of subjects: 0
Study 17398083 — intervention group
Group type: COMPARATOR
Intervention: T‐gel
Number of subjects: 0
Study 17398083 — intervention group
Group type: COMPARATOR
Intervention: EMLA cream
Number of subjects: 0
Study 11955535 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen A: zidovudine plus lamivudine starting at 36 weeks' gestation, followed by oral intrapartum dosing and by 7 days' postpartum dosing of mothers and infants.
Number of subjects: 1797
Study 11955535 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen B: as regimen A, but without the prepartum component.
Number of subjects: 1797
Study 11955535 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen C: intrapartum zidovudine and lamivudine only.
Number of subjects: 1797
Study 11955535 — intervention group
Group type: COMPARATOR
Intervention: Placebo group.
Number of subjects: 1797
Study 9848308 — intervention group
Group type: EXPERIMENTAL
Intervention: Endothelial nitric oxide synthase (eNOS) staining on spermatozoa
Number of subjects: 12
Study 9848308 — intervention group
Group type: COMPARATOR
Intervention: Control slides incubated with preabsorbed antibody or mouse immunoglobulin G
Number of subjects: 12
Study 7527733 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (CDDP)
Number of subjects: 64
Study 7527733 — intervention group
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Number of subjects: 64
Study 7527733 — intervention group
Group type: EXPERIMENTAL
Intervention: Vincristine, Ifosfamide, and Peplomycin (VIP)
Number of subjects: 64
Study 7527733 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, Doxorubicin, and CDDP (CAP)
Number of subjects: 64
Study 7527733 — intervention group
Group type: EXPERIMENTAL
Intervention: Ifosfamide, Doxorubicin, and CDDP (IAP)
Number of subjects: 64
Study 7527733 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoposide, Doxorubicin, and CDDP (EAP)
Number of subjects: 64
Study 7527733 — intervention group
Group type: COMPARATOR
Intervention: Single agents plus VIP
Number of subjects: 64
Study 7527733 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy regimens (all)
Number of subjects: 64
Study 7527733 — intervention group
Group type: EXPERIMENTAL
Intervention: PSA doubling time
Number of subjects: 64
Study 2657058 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine 10 mg once daily
Number of subjects: 22
Study 2657058 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 20 mg twice daily
Number of subjects: 22
Study 1059513 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual toothbrushes with instruction and motivation (Groups 2 and 3)
Number of subjects: 123
Study 1059513 — intervention group
Group type: EXPERIMENTAL
Intervention: Electric toothbrush (Touch Tronic, Teledyne Aqua Tec) with instruction and motivation (Group 4)
Number of subjects: 123
Study 1059513 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group 1)
Number of subjects: 123
Study 30784127 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep hygiene education and reflexology
Number of subjects: 167
Study 30784127 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 167
Study 27748620 — intervention group
Group type: EXPERIMENTAL
Intervention: CCT plus availability of EI in the community (T1)
Number of subjects: 1113
Study 27748620 — intervention group
Group type: EXPERIMENTAL
Intervention: CCT plus promotion of the EI program by the CCT program (T2)
Number of subjects: 1113
Study 27748620 — intervention group
Group type: COMPARATOR
Intervention: CCT only (T0)
Number of subjects: 1113
Study 24740588 — intervention group
Group type: EXPERIMENTAL
Intervention: 750 ml of fresh coffee brew
Number of subjects: 84
Study 24740588 — intervention group
Group type: COMPARATOR
Intervention: 750 ml of water
Number of subjects: 84
Study 23220425 — intervention group
Group type: EXPERIMENTAL
Intervention: Collapsing variant
Number of subjects: 138
Study 23220425 — intervention group
Group type: EXPERIMENTAL
Intervention: Not otherwise specified FSGS
Number of subjects: 138
Study 23220425 — intervention group
Group type: EXPERIMENTAL
Intervention: Tip variant
Number of subjects: 138
Study 23220425 — intervention group
Group type: EXPERIMENTAL
Intervention: Tip or collapsing variants
Number of subjects: 138
Study 21895503 — intervention group
Group type: EXPERIMENTAL
Intervention: Metal-backed (MB) tibial components
Number of subjects: 9
Study 21895503 — intervention group
Group type: COMPARATOR
Intervention: All-polyethylene (AP) tibial components
Number of subjects: 9
Study 19951555 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine-enriched enteral nutrition (0.5 g x kg(‐1) x d(‐1))
Number of subjects: 33
Study 17116184 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional therapy plus Sweet Talk
Number of subjects: 126
Study 17116184 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy and Sweet Talk
Number of subjects: 126
Study 17116184 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 126
Study 15084240 — intervention group
Group type: EXPERIMENTAL
Intervention: Red clover-derived isoflavone supplement (26 mg biochanin A, 16 mg formononetin, 1 mg genistein, 0.5 mg daidzein)
Number of subjects: 205
Study 15084240 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 205
Study 15084240 — intervention group
Group type: EXPERIMENTAL
Intervention: Red clover-derived isoflavone supplement
Number of subjects: 205
Study 12396863 — intervention group
Group type: EXPERIMENTAL
Intervention: Median sensory nerve conduction velocity (SNCV) from digit 1 to wrist
Number of subjects: 213
Study 12396863 — intervention group
Group type: EXPERIMENTAL
Intervention: Median SNCV D/P ratio from palm to digit 3/palm to wrist
Number of subjects: 213
Study 12396863 — intervention group
Group type: EXPERIMENTAL
Intervention: Median SNCV digit 1 to wrist
Number of subjects: 213
Study 12396863 — intervention group
Group type: EXPERIMENTAL
Intervention: Median SNCV D/P ratio
Number of subjects: 213
Study 9377115 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbinoxamine-pseudoephedrine (Group A)
Number of subjects: 48
Study 9377115 — intervention group
Group type: COMPARATOR
Intervention: Astemizole-pseudoephedrine (Group B)
Number of subjects: 48
Study 8321577 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (200 mg)
Number of subjects: 0
Study 8321577 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphenhydramine (25 mg)
Number of subjects: 0
Study 31328535 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional connectivity MRI (fcMRI)
Number of subjects: 93
Study 31328535 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal CRF combining top 100 variables from each modality
Number of subjects: 93
Study 31328535 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal CRF combining 19 top variables reaching >67% accuracy
Number of subjects: 93
Study 31328535 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal CRF with reduced initial variables using a less granular region of interest scheme
Number of subjects: 93
Study 31328535 — intervention group
Group type: EXPERIMENTAL
Intervention: Random selection of 100 variables per modality
Number of subjects: 93
Study 29205592 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary guidance to restrict polyphenol-rich foods
Number of subjects: 75
Study 29205592 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal pregnancies)
Number of subjects: 75
Study 26301385 — intervention group
Group type: EXPERIMENTAL
Intervention: Enthesis‐Dextrose
Number of subjects: 73
Study 26301385 — intervention group
Group type: COMPARATOR
Intervention: Enthesis‐Saline
Number of subjects: 73
Study 26301385 — intervention group
Group type: COMPARATOR
Intervention: Superficial‐Saline
Number of subjects: 73
Study 26301385 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 73
Study 24760656 — intervention group
Group type: EXPERIMENTAL
Intervention: OLM/AML/HCTZ 20/5/12.5 mg
Number of subjects: 2509
Study 24760656 — intervention group
Group type: EXPERIMENTAL
Intervention: OLM/AML/HCTZ 40/5/12.5 mg
Number of subjects: 2509
Study 24760656 — intervention group
Group type: EXPERIMENTAL
Intervention: OLM/AML/HCTZ 40/5/25 mg
Number of subjects: 2509
Study 24760656 — intervention group
Group type: EXPERIMENTAL
Intervention: OLM/AML/HCTZ 40/10/12.5 mg
Number of subjects: 2509
Study 24760656 — intervention group
Group type: EXPERIMENTAL
Intervention: OLM/AML/HCTZ 40/10/25 mg
Number of subjects: 2509
Study 22175654 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 16
Study 22175654 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 20026953 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhomogeneous static magnetic field (SMF, 0 to 192 mT peak‐to‐peak magnetic flux density and 19 T/m lateral gradient) exposure for 30 minutes
Number of subjects: 59
Study 20026953 — intervention group
Group type: COMPARATOR
Intervention: Sham exposure (placebo)
Number of subjects: 59
Study 18446025 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugar-free gum containing 54 mg CPP-ACP
Number of subjects: 2720
Study 18446025 — intervention group
Group type: COMPARATOR
Intervention: Control sugar-free gum without CPP-ACP
Number of subjects: 2720
Study 17309715 — intervention group
Group type: EXPERIMENTAL
Intervention: Nerve stimulator-guided occipital nerve blockade
Number of subjects: 50
Study 17309715 — intervention group
Group type: COMPARATOR
Intervention: Preservative-free normal saline (control)
Number of subjects: 50
Study 12692482 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 30
Study 12692482 — intervention group
Group type: EXPERIMENTAL
Intervention: PTSD group
Number of subjects: 30
Study 10749610 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic resection (n = 17)
Number of subjects: 34
Study 10749610 — intervention group
Group type: COMPARATOR
Intervention: Open resection (n = 17)
Number of subjects: 34
Study 10749610 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 34
Study 8958892 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol 50 micrograms twice daily (n = 22)
Number of subjects: 31
Study 8958892 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 9)
Number of subjects: 31
Study 8958892 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol 50 micrograms twice daily
Number of subjects: 31
Study 1311648 — intervention group
Group type: EXPERIMENTAL
Intervention: Human-alpha atrial natriuretic factor (1-28) at a dose of 1.2 pmol min-1 kg-1
Number of subjects: 8
Study 1311648 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 3004088 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.20 mg kg‐1 etomidate
Number of subjects: 19
Study 3004088 — intervention group
Group type: COMPARATOR
Intervention: 3.15 mg kg‐1 thiopental
Number of subjects: 19
Study 30206045 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-transplant complications before day 100 (including relapse, lack of platelet recovery, grade-II acute GVHD, grade-III/IV acute GVHD)
Number of subjects: 784
Study 29619605 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin
Number of subjects: 14
Study 29619605 — intervention group
Group type: EXPERIMENTAL
Intervention: Meloxicam
Number of subjects: 14
Study 27824979 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate loading with a nonoccluding temporary crown within 24 hours after implant placement
Number of subjects: 62
Study 27824979 — intervention group
Group type: COMPARATOR
Intervention: Conventional loading according to a two-stage procedure after 3 months
Number of subjects: 62
Study 24398317 — intervention group
Group type: EXPERIMENTAL
Intervention: Nigella Sativa oil (NSO)
Number of subjects: 42
Study 24398317 — intervention group
Group type: COMPARATOR
Intervention: Isotonic sodium chloride solution (ISCS)
Number of subjects: 42
Study 22800984 — intervention group
Group type: EXPERIMENTAL
Intervention: Interview-Group (IG)
Number of subjects: 109
Study 22800984 — intervention group
Group type: COMPARATOR
Intervention: Non-Interview Group (NIG)
Number of subjects: 109
Study 20424539 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran
Number of subjects: 0
Study 20424539 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 0
Study 17478034 — intervention group
Group type: EXPERIMENTAL
Intervention: Propionyl L‐carnitine (PLC) alone (2 g/d)
Number of subjects: 32
Study 17478034 — intervention group
Group type: EXPERIMENTAL
Intervention: Propionyl L‐carnitine (PLC) plus sildenafil (50 mg/d twice weekly)
Number of subjects: 32
Study 17478034 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil alone (50 mg/d twice weekly)
Number of subjects: 32
Study 17478034 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 15620433 — intervention group
Group type: EXPERIMENTAL
Intervention: rosiglitazone (4 mg per day for 12 weeks)
Number of subjects: 125
Study 12015683 — intervention group
Group type: EXPERIMENTAL
Intervention: GA combined with retrobulbar block (group B)
Number of subjects: 75
Study 12015683 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia (GA) alone (group A)
Number of subjects: 75
Study 12015683 — intervention group
Group type: COMPARATOR
Intervention: GA combined with peribulbar block (group C)
Number of subjects: 75
Study 10623334 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 micrograms of procaterol with large-volume spacer
Number of subjects: 14
Study 10623334 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 micrograms of procaterol with small-volume spacer
Number of subjects: 14
Study 10623334 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 micrograms of procaterol with MDI alone
Number of subjects: 14
Study 10623334 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 micrograms of procaterol with small-volume spacer
Number of subjects: 14
Study 10623334 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 micrograms of procaterol with large-volume spacer
Number of subjects: 14
Study 10623334 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower procaterol dose via large-volume spacer
Number of subjects: 14
Study 7800305 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy
Number of subjects: 1081
Study 7800305 — intervention group
Group type: COMPARATOR
Intervention: Control group (no hormone replacement therapy)
Number of subjects: 1081
Study 1983370 — intervention group
Group type: EXPERIMENTAL
Intervention: Silymarin
Number of subjects: 40
Study 1983370 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino‐imidazole‐carboxamide‐phosphate
Number of subjects: 40
Study 1983370 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 570272 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone 50 mg
Number of subjects: 10
Study 570272 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone 100 mg
Number of subjects: 10
Study 570272 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31789898 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 10 mg in 2.5 ml saline (4 mg/ml)
Number of subjects: 60
Study 31789898 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 10 mg in 5 ml saline (2 mg/ml)
Number of subjects: 60
Study 31789898 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 10 mg in 10 ml saline (1 mg/ml)
Number of subjects: 60
Study 31789898 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 10 mg in 15 ml saline (0.67 mg/ml)
Number of subjects: 60
Study 31789898 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 10 mg in 20 ml saline (0.5 mg/ml)
Number of subjects: 60
Study 31520895 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Exercise (RE)
Number of subjects: 406
Study 31520895 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise (AE)
Number of subjects: 406
Study 31520895 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined RE and AE (CE)
Number of subjects: 406
Study 31520895 — intervention group
Group type: COMPARATOR
Intervention: No exercise control group
Number of subjects: 406
Study 28577580 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncertain threat (participants were told they would flip a coin to determine if they would give a speech)
Number of subjects: 79
Study 28577580 — intervention group
Group type: COMPARATOR
Intervention: Certain threat (participants were told they would give a speech)
Number of subjects: 79
Study 28577580 — intervention group
Group type: COMPARATOR
Intervention: Both uncertain and certain threat conditions
Number of subjects: 79
Study 25681448 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed-release dimethyl fumarate (DMF) 240 mg twice daily (BID)
Number of subjects: 1417
Study 25681448 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed-release dimethyl fumarate (DMF) 240 mg three times daily (TID)
Number of subjects: 1417
Study 25681448 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed-release dimethyl fumarate (DMF)
Number of subjects: 1417
Study 25681448 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1417
Study 25681448 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous glatiramer acetate 20 mg once daily (active reference comparator)
Number of subjects: 1417
Study 23975067 — intervention group
Group type: EXPERIMENTAL
Intervention: Small-group training
Number of subjects: 96
Study 23975067 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based training
Number of subjects: 96
Study 23975067 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 96
Study 21277255 — intervention group
Group type: EXPERIMENTAL
Intervention: ramelteon 4 or 8 mg, titrated up to 16 mg if necessary for 24 weeks
Number of subjects: 190
Study 19071061 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 1076
Study 19071061 — intervention group
Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 1076
Study 17257711 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 hours of didactic instruction and an 8-week perinatal clinical rotation
Number of subjects: 273
Study 17257711 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 273
Study 12871873 — intervention group
Group type: EXPERIMENTAL
Intervention: FSH priming (75 IU rFSH for 6 days)
Number of subjects: 60
Study 12871873 — intervention group
Group type: COMPARATOR
Intervention: Non-FSH priming (no FSH stimulation)
Number of subjects: 60
Study 12871873 — intervention group
Group type: EXPERIMENTAL
Intervention: FSH priming
Number of subjects: 60
Study 11189538 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical hyperbaric oxygen at 1.004 to 1.013 atmospheres (THOT)
Number of subjects: 40
Study 11189538 — intervention group
Group type: COMPARATOR
Intervention: Standard wound care (SWC)
Number of subjects: 40
Study 9362185 — intervention group
Group type: EXPERIMENTAL
Intervention: tinidazole 500 mg b.i.d.
Number of subjects: 113
Study 9362185 — intervention group
Group type: COMPARATOR
Intervention: tetracycline 500 mg b.i.d.
Number of subjects: 113